Insider

Alcon Inc

ALC Salud · 1 análisis

Qué cambió

Historial de la empresa

Octubre 2026

ALCON INC: 12 recorded developments from 5 official sources in 2026-10.

  • 2026-09-28: Attendees will have opportunities to engage with Alcon innovations through the WaterInnovations™ Immersive Experience, MARLO demonstrations and an Innovation Suite featuring Voyager™ DSLT and the Valeda® PBM device at Academy 2026. Fuente
  • 2026-09-28: The Innovation Suite will feature Voyager DSLT and Valeda PBM, giving optometrists an opportunity to learn about technologies supporting care for glaucoma and dry age-related macular degeneration patients. Fuente
  • 2026-09-28: Alcon helps more than 260 million people in over 140 countries and territories each year with eye conditions and employs more than 25,000 associates enhancing quality of life through innovative products and programs. Fuente
  • 2026-09-28: TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease and should not be administered while wearing contact lenses; lenses may be reinserted 15 minutes following administration. Fuente
  • 2026-09-28: The Voyager DSLT device is an automated ophthalmic laser device for direct selective laser trabeculoplasty that uses a Q-switched, 3-ns pulse width, frequency-doubled Nd:YAG laser at 532 nm, directs a 400-μm beam to the limbus without contact, and uses image-processing and eye-tracking a Fuente
  • 2026-09-29: Featured innovations include the UNITY platform, highlighted by the new UNITY M ophthalmic microscope, along with Clareon PanOptix Pro, Clareon TruPlus IOLs, Valeda Photobiomodulation (PBM) and Voyager DSLT. Fuente
  • 2026-09-29: Alcon's more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Fuente
  • 2026-09-29: In July 2026, Alcon and Aravind launched the Aravind Retina Centre of Excellence in Coimbatore, India, a dedicated training facility designed to expand retina education, facilitate knowledge exchange and provide hands-on learning opportunities for Eye Care Professionals in India and beyo Fuente
  • 2026-09-29: In 2024, Alcon and Aravind launched the Global Centre of Excellence for advanced cataract surgery training, helping equip surgeons with the skills and technologies needed to deliver high-quality care. Fuente
  • 2026-10-01: Alcon (SIX/NYSE: ALC) announced new investigator-initiated clinical data demonstrating that SYSTANE® PRO Preservative-Free (PF) provided clinically comparable dry eye symptom relief to MIEBO^ (perfluorohexyloctane ophthalmic solution), meeting the study's primary endpoint of non-inferior Fuente
  • 2026-10-20: Alcon acquired Neurotech Pharmaceuticals, Inc. Fuente
  • 2026-10-20: Alcon's acquisition of Neurotech includes ENCELTO (revakinagene taroretcel-lwey), an encapsulated cell therapy intended for surgical intravitreal implantation. Fuente

Los registros mensuales los redacta la IA a partir de los informes y fuentes oficiales verificados de cada mes (en inglés, tal como se extrajeron), y cada línea enlaza su fuente; las líneas argumentales agrupan hechos relacionados entre análisis mediante embeddings vectoriales (Amazon Titan Text Embeddings V2). Contexto provisional, no es asesoramiento de inversión.

Comparables del sector

Comparación con 36 empresas seguidas en Salud (mediana de ingresos +7,2% a/a), según datos XBRL de la SEC.

EmpresaÚltimos ingresosIngresos a/aMargen operativo
Alcon Inc ALC———
Unitedhealth Group Inc UNH113 mil M $-0,4%5,8%
Mckesson Corp MCK111 mil M $+7,6%1,4%
CVS Health Corp CVS108 mil M $+5,4%3,3%
Cigna Group CI73,7 mil M $+5,6%3,3%
Cardinal Health Inc CAH67,5 mil M $+5,5%1,1%
Elevance Health, Inc. ELV51,4 mil M $+1,4%2,5%

Último periodo reportado por empresa en SEC CompanyFacts (XBRL). Los calendarios fiscales pueden diferir.

Grandes fondos (13F)

FondoAccionesValorCambio en accionesTrimestre
Norges Bank (Norway's sovereign fund)10.976.697$741.431.995—T2 2026
Fidelity (FMR)7.567.130$489.960.885-1,3%T3 2026
D. E. Shaw & Co.2.918.650$188.982.588+57,1%T3 2026
Two Sigma Investments2.030.060$131.446.385+346,6%T3 2026
Citadel Advisors684.878$44.345.851+73,2%T3 2026
BlackRock638.773$41.360.589-1,8%T3 2026
Wellington Management114.082$7.375.467+1,4%T3 2026
Millennium Management106.204$6.876.709+470,6%T3 2026
Bridgewater Associates28.891$2.176.937—T1 2026
State Street6123$396.4640,0%T3 2026

De los informes trimestrales 13F-HR de los grandes fondos que seguimos, tal como se presentaron. Los fondos informan hasta 45 días después del cierre del trimestre, por lo que las posiciones pueden haber cambiado. Cambio: frente al trimestre anterior del mismo fondo. No es una recomendación.